Treatment of hyperphosphatemia with Tenapanor in Laos: indications, dosage, and analysis of drug interactions
Tenapanor, as a selective NHE3 inhibitor, is mainly used for the treatment of hyperphosphatemia in dialysis patients with chronic kidney disease. It exerts its effect by inhibiting intestinal phosphorus absorption and must strictly follow the principle of administration with meals, while paying attention to the risk of interaction with specific drugs.
Indications for Tenapanor
1. Core indications
Approved as an adjuvant therapy for hyperphosphatemia in adult patients undergoing dialysis for chronic kidney disease, it should be used in combination with dietary control and phosphate binders.
2. Target audience
Especially suitable for patients who are intolerant or have poor efficacy with traditional phosphate binders, as well as dialysis patients who need to avoid calcium/aluminum load.
Usage and dosage specifications for Tenapanor
3. Basic dosing regimen
The initial dose is 400mg twice daily (800mg/day) and must be taken with the main meal to achieve optimal efficacy.
4. Principle of dose adjustment
Adjust blood phosphorus levels every 2-4 weeks, with a maximum increase or decrease of 200mg/day and a maximum of 3000mg/day, and require strict monitoring by a doctor.
Drug interactions of Tenapanor
5. Effects of antacids
Aluminum/magnesium antacids can reduce the efficacy of Tenapano and should be taken at least 2 hours apart. It is recommended to prioritize the use of H2 receptor antagonists.
6. Iron agent interaction
There is a risk of binding reaction with oral iron supplements, and they should be taken at intervals of at least 1 hour. Intravenous iron supplementation is not affected.
7. Special precautions
At present, no significant interaction with CYP450 enzyme drugs has been found, but the combination of potent P-gp inhibitors requires careful monitoring.
Taboos and caution of Tenapanor
8. Absolute taboos
Patients with intestinal obstruction are prohibited from using medication, and medication should be suspended during the acute phase of severe diarrhea or inflammatory bowel disease.
9. Relative taboos
Patients with severe liver dysfunction should use caution. The safety during pregnancy has not been established, and the pros and cons should be weighed during lactation.
Disclaimer：《Treatment of hyperphosphatemia with Tenapanor in Laos: indications, dosage, and analysis of drug interactions》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！